Outcome of board meeting of OneSource Specialty Pharma
The Board of OneSource Specialty Pharma at its meeting held on 04 August 2025 has given their in-principle approval to evaluate potential acquisition of the Sterile Injectable CDMO and CMO businesses of Steriscience and Carbapenem facility of Brooks Steriscience.
The potential transaction, if finalised and consummated, will bring in the following facilities into OneSource:
- USFDA-approved sterile fill-finish manufacturing facility in Warsaw, Poland, with the ability to expand capacity for drug-device combination products for our global partners. This site serves marquee global players and several IP-led products. h
- An integrated, state-of-the-art, USFDA-approved carbapenem facility in Vadodara, India operated under the name of Brooks Steriscience.
Steriscience SG and Brooks Steriscience Limited are majorly owned directly/ indirectly by the Promoters of the Company.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
14 minutes ago
- Time of India
India to Get First Commercial Compound Semiconductor Fab in Odisha
/ Aug 12, 2025, 10:46PM IST The Union Cabinet, chaired by Prime Minister Narendra Modi, has approved four new semiconductor projects worth ₹4,600 crore under the India Semiconductor Mission. These include India's first commercial compound semiconductor fabrication unit, an advanced glass-based packaging facility, and manufacturing plants in Odisha, Punjab, and Andhra Pradesh. Expected to create over 2,000 skilled jobs, the projects will support sectors such as telecom, EVs, defence, and consumer electronics, raising total ISM-approved investments to ₹1.6 lakh crore across 10 projects in six states.#indiasemiconductormission #pmmodi #semiconductor #chipmanufacturing #technology #electronics #makeinindia #atmanirbharbharat #odisha #andhrapradesh #punjab #ev #defence
News18
5 hours ago
- News18
Zetwerk acquires majority stake in KRYFS power component
Agency: PTI Last Updated: New Delhi, Aug 12 (PTI) Zetwerk Manufacturing Businesses Pvt Ltd on Tuesday said it has acquired a controlling stake in KRYFS Power Components, a market leader in transformer solutions. The acquisition creates one of India's most formidable players in electricals and renewables manufacturing, a statement said. It blends Zetwerk's digital-first supply chain platform and global manufacturing network with KRYFS's deep domain expertise, NABL-accredited labs, POWERGRID-approved facilities (up to 765 kV), and 10 fully operational plants across the country. KRYFS is the only company in India to manufacture 765 KV class transformer laminations and transformer tanks, it stated. 'This partnership isn't just about scale, it's about shaping the next generation of infrastructure manufacturing solutions in India, for India and for the world," said Amrit Acharya, CEO and Co-founder, Zetwerk. KRYFS' existing management team, including its CEO, will continue to lead the company, ensuring continuity and stability through this new chapter. KRYFS' 1,600+ employees, spread across its 10 plants, will now be part of Zetwerk's digitally enabled, high-performance ecosystem. 'At Zetwerk, we've always believed that India can be the global factory for critical infrastructure and energy solutions. This partnership with KRYFS reinforces that belief," said Srinath Ramakkrushnan, COO and Co-founder of Zetwerk. PTI KKS ANU view comments First Published: August 12, 2025, 18:45 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Time of India
9 hours ago
- Time of India
Veerendra Battula: The Mind Behind Patents, Publications, and the PupilDx Breakthrough
In an age where technology is rewriting the boundaries of possibility, few names embody the intersection of innovation, leadership, and impact quite like Veerendra Battula. Known in professional circles as a visionary in cloud architecture, DevOps transformation, and AI-driven solutions, Battula has built a career that bridges enterprise IT excellence with cutting-edge healthcare technology. Over the past decade, Battula has led transformative digital initiatives for enterprises seeking not only to modernise their IT systems but also to future-proof them. His expertise spans multi-cloud environments, containerised applications, infrastructure security, and sustainable IT frameworks—capabilities that have made him a sought-after advisor for technology-driven organisations in India and abroad. But Battula's journey is not defined solely by corporate success. His thought leadership has reached academic, research, and policy-making communities through numerous high-profile conferences, where he has participated virtually as a keynote speaker, jury member, advisory board contributor, and editorial board member. His insights have been featured at premier Indian events focusing on cloud innovation, AI applications in healthcare, enterprise digital transformation, and cybersecurity resilience. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Use an AI Writing Tool That Actually Understands Your Voice Grammarly Install Now Undo Innovation That Goes Beyond the Cloud Battula's impact is measured not just by speeches delivered but by tangible intellectual contributions. With several peer-reviewed publications and a growing citation record to his name, he has established himself as an active contributor to the global knowledge economy. His patent portfolio reflects this commitment, including a UK-approved patent and a corresponding Indian patent currently under evaluation, which is expected to receive approval in the coming months. Perhaps most notably, Battula received widespread recognition for his breakthrough research article titled 'PupilDx: Novel AI-driven Pupillary Device for Non-Invasive Neurological Risk Screening,' published in the International Journal for Multidisciplinary Research . The article introduced a pioneering device that uses AI to analyse pupillary response, enabling early detection of potential neurological risks without invasive procedures. Since its publication, PupilDx has gained significant momentum in both academic circles and healthcare technology forums, sparking discussions on its potential for preventive neurology in India's public health system. Shaping the Future of AI in Healthcare Speaking on his motivation, Battula says, 'Innovation is meaningful only when it solves a real problem. My focus is to align advanced technologies like AI and cloud infrastructure with human well-being, ensuring they are scalable, secure, and accessible.' Looking ahead, Battula is working on expanding the application of AI in diagnostics, exploring possibilities for portable, cloud-connected medical devices that can bring advanced screening to rural and underserved areas. His vision includes integrating sustainable IT practices into healthcare systems, ensuring that next-generation solutions are not only effective but also energy-efficient and environmentally conscious. From boardrooms to virtual conference stages, from patent offices to peer-reviewed journals, Veerendra Battula's career is a testament to how technical mastery, research excellence, and social impact can converge. As India navigates its next decade of technological advancement, innovators like Battula are ensuring the country's journey is both globally competitive and locally relevant.
